Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will secure the preparation on Odimma's First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.
Lead Product(s): ODI-2001
Therapeutic Area: Oncology Product Name: ODI-2001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Capital Grand Est
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Financing May 02, 2023
Details:
Odimma will gain access to Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology, providing them with a clinical supply of personalised dbDNA™, to support and underpin the development of their candidate immunotherapy cancer treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Touchlight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2022
Details:
ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing personalized neoantigens.
Lead Product(s): ODI-2001
Therapeutic Area: Oncology Product Name: ODI-2001
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: ABL Europe
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2022